US-based telehealth company Hims & Hers Health Inc. saw its stock value plummet as much as 20% in after-market trading on Monday due to a decision to stop selling commercially-available doses of semaglutide, the main ingredient in popular weight-loss medications Ozempic and Wegovy. The move comes after Novo Nordisk’s drugs were removed from the FDA shortage list last week. Despite this, Hims will continue to sell personalized versions of these medications, which contain minor tweaks to existing formulations.
Source: https://www.bloomberg.com/news/articles/2025-02-24/hims-2025-sales-outlook-beats-despite-weight-loss-uncertainty